Ceftriaxone is manufactured by multiple sterile-injectable companies, including Roche, Sandoz, Hikma, Fresenius Kabi, and other approved generic manufacturers. AdvaCare Pharma also manufactures ceftriaxone sodium for injection for international distribution.
Answer
Ceftriaxone is a third-generation cephalosporin originally marketed by Roche under the brand Rocephin. It is now a multisource injectable antibiotic produced by numerous generic and hospital-injectable manufacturers. Current suppliers vary by country and may include Sandoz, Hikma, Fresenius Kabi, and other approved manufacturers.
Ceftriaxone is generally supplied as sterile ceftriaxone sodium powder requiring reconstitution. Common vial strengths include 250mg, 500mg, 1g, and 2g, although registered presentations vary. Combination products, such as ceftriaxone with sulbactam, are available in selected markets but are not interchangeable with ceftriaxone alone.
Because ceftriaxone is a sterile injectable beta-lactam, manufacturer evaluation should address:
• Sterile-facility inspection history
• Aseptic processing or sterilization validation
• Beta-lactam segregation and contamination controls
• Particulate matter and container-closure integrity
• Reconstitution time, clarity, and solution stability
• API source and impurity controls
• Vial, stopper, and packaging compatibility
• Dossier and pharmacopoeial compliance
AdvaCare Pharma manufactures ceftriaxone sodium for injection in multiple vial strengths for international distributors and healthcare institutions. It should be evaluated as a qualified B2B option through technical-document review, registration status, samples, and supply-capacity assessment.

Trust Our Expert Answers?
Source Ceftriaxone Injection
Review ceftriaxone sodium vial strengths, packaging options, and regulatory documentation for hospital and distributor supply.

